Our digital biomarker has several applications across the health continuum, with the first two being: - pharma as a recruity screen and surrogate endpoint marker for more objective clinical trial efficiency measures for dementia therapeutics. - neurologic providers, especially for telehealth, to longitudinally track their patients’ dementia progression.
-Raised $2M Seed funding from marquee institutions such as NVIDIA, One Medical Group, Temasek/Vertex. - 10 patents pending around digital biomarkers platform tech, health applications leveraging optical modality + AI tech - Accepted into 3 large-tech accelerators: NVIDIA, Microsoft, IBM - 5 U.S. Senator meetings with invitations to DC to demo tech (Jan 2021) - Ongoing BD due diligence with several large-Pharma and Payors - Tremendous Health + Tech industry recognition across industry conferences, competitions, and press: Forbes, NVIDIA, HIMSS, UC Office of President, HLTH 2018 and 2019, HIMSS 2019, more. - BioTrillion is now the #1 Google search result for: “Digital Biomarker Startups” - BioTrillion is one of the top 10 startups featured by NVIDIA at their annual AI conference: https://www.nvidia.com/en-us/gtc/topics/ai-startups/ - POC of PLR digital biomarker (at accuracy and reproducibility of 90%+) - Our AI-powered App can now quantitatively measure anomalies in Motor and Cognitive brain function, namely detecting motor (drug use) and cognition changes
Our BioEngine4D solution addresses a market opportunity of digital biomarkers highlighted by over 3 billion smartphone users, already interested in better monitoring their health. In the U.S., smartphone market penetration is now 80% of adults, and 45% of American smartphone users use an iPhone. Our primary application focuses on neurodegenerative diseases, including Alzheimer’s Disease (AD). The US has 5.5 million AD patients, with 44 million worldwide. As interventional trials move into earlier stages of neurodegenerative diseases, the need for sensitive biomarkers present in early AD amplifies and new digital biomarkers are already being incorporated into clinical trials. Additionally, the Pharma and Payor markets are $8B each and grow beyond that with the inclusion of other disease target areas as well. BioTrillion's mission: enabling smart device technology to empower ordinary consumers with extraordinary health abilities. Our goal is to democratize healthcare by making it more affordable, accessible, and convenient than in a traditional medical setting.
Problem or Opportunity
Detecting brain diseases and disorders have been fundamentally limited to qualitative “assessments.”The healthcare industry continues to search for more objective and innovative quantitative “measures.”
“A patient cannot be assessed during a 15-minute visit to the clinic….We are looking for a battery of measures that are more precise, less subjective, at numerous touchpoints during the patient’s day.” - Danny Bar-Zohar, Global Head of Neuroscience @ Merck
“The need for personalized treatment for neurological conditions is clear….partnerships between pharma and tech are the next logical step for this industry.” - Erik Janssen, Vice President of Neurology @ UCB Pharma
Solution (product or service)
We're developing a digital biomarker platform called BioEngine4D - to digitally detect developing diseases - by innovating at the intersection of Computer Vision and Physiology. Our AI-based platform quantifies and computes key features in the eyes and face via our mobile App, with applications for real-time drug-use detection and early neurologic disease detection. Our mission is to enable ordinary consumers with extraordinary health abilities – using only the smartphone already owned by over 1 billion global consumers.
The digital biomarker space is still nascent, but rapidly emerging. The following digital health and digital biomarker companies would be “comps” (at a high level): • Verily Life Sciences (subsidiary of Google): many healthcare projects with a focus area in digital biomarkers; however, largely uses internally developed hardware (https://verily.com/) • Evidation Health: an online engine to measure + analyze behavioral data points from wearable technology (https://evidation.com/) • Mindstrong Health: a mobile app platform to measure digital biomarkers for behavioral health (https://mindstrong.com/) • Brightlamp: measures pupillary light reflex utilizing the rear camera and flash of an iPhone to detect acute diseases such as concussions and traumatic brain injury. This validates the ability of an iPhone to measure PLR, albeit not being explored to its full potential (https://reflexapp.io/)
Advantages or differentiators
Our differentiation – technological and business – relative to our competitors is unique and unconventional even for an emerging niche within healthcare:
1. BioTrillion flips the traditional paradigm by approaching innovation with: ""what physiologic features can 1B+ Consumers measure, then what diseases do they biomark to?"" Vs. ""what is the disease of focus, then how can a Clinician measure it.""
2. BioTrillion is focused on novel “digital biomarkers” for early disease detection; whereas, 99% of consumer health solutions on the market are more focused on Wellness solutions for disease prevention by primarily using kinetic HR sensors.
3. BioTrillion’s core innovative focused is at the intersection of Physiology and Computer Vision applied to Health. Smartphone optical hardware sensors and processors continuously improve every year, enabling BioTrillion to develop more powerful digital biomarker applications – now and into the future.
BioTrillion is now the #1 Google search result for: "Digital Biomarker Startups"
Our PxR digital biomarker technology will be deployed in a multi-market staggered GTM approach, progressing across each stakeholder in the healthcare continuum. Initially with clinical enterprises (B2B2C), then directly to consumers (B2C) as validation and familiarity increases.
Our digital biomarkers have monetizable applications with financial growth commensurate with digital scalability. Projected gross revenues for 2022E, 2023E, and 2024E are $23M, $51M, $78M, respectively and projected EBITDA of $15M, $35M, $52M, respectively.
Our PxR neurologic digital biomarkers will be commercialized via a multi-market staggered GTM approach, across the primary stakeholders in the neurologic healthcare continuum: 1. Pharma Predictive Biomarker: Clinical trials recruitment Pharmacodynamic Biomarker: Clinical trials response (P1/2) Surrogate Endpoint Biomarker: Clinical trials efficacy (P3) 2. Provider (Telehealth) Prognostic-Monitoring Biomarker: Identifying likelihood of disease recurrence and tracking progression over time. 3. Payor: Risk Biomarker: Early disease detection (pre-Dx)"
Money will be spent on
Our uses of capital are predominantly for additional clinical validation trials and commercialization, as follows: Clinical Validation:
Pilot observational trials to clinically validate PxR digital biomarker in 1 acute + 1 chronic neuro indication Launch and Commercialization:
Additional hires: Director of Operations, Clinical Operations, Business Development PxR mobile app product development finalization R&D for additional digital biomarkers:
Expansion of our technology platform and Computer Vision team to extend into new feature sets for additional digital biomarkers of more diseases We can reach organic FCF+ without needing any subsequent financing
Offer for investor
We are raising an $8M Series-A in mid-2021.
We've previously raised a $2.2M seed round, via SAFE instrument ($35M cap, 20% discount) with investors from marques institutions across the health and tech domains.
BioTrillion’s goals are a moonshot and represents a compelling investment opportunity with a massively asymmetric reward-risk profile. The following represent what we believe to be the greatest risks; along with their mitigants:
Risks: Delayed Pharma and Payor revenue partnerships while cash burn and R&D costs continue
Mitigants: Conservative burn; Founder has chosen to forego a salary from inception to date. Additional investments and non-dilutive grant funding interest.
Risks: Low reproducibility and accuracy of PxR measures.
Mitigants: Approaching with 2 technical methods to analyze PLR: convolutional neural network (CNN) and classical image processing techniques. Training of CNN with large quantum and variety of image data for maximum classification accuracy.
Risks: Inability of PxR digital biomarker to statistically significantly detect Alzheimer’s disease.
Mitigants: R&D is premised on causal neurophysiologic pathways and we’ve already achieve the first steps of validation by being able to detect drug use. Additional biomarker detection targets provide “multiple shots on goal” to hedge risk: Acute Trauma (Stroke, Concussion), Parkinson’s disease, Non-health targets.
Risks: Ineffective go-to-market strategy and poor interest + engagement from Consumers.
Mitigants: Strategic and financial decision to focus on a post-diagnosis solution for Pharma first, to provide validation for Providers and Payors for a broader solution. Increase in breadth of disease targets over time, branching out from Alzheimer’s to other neurological + dermatological conditions to attract a wider/younger user base.
Risks: Competitors with first-mover advantage, existing market share, and higher brand recognition (Apple, Google, Amazon).
Mitigants: Focus on Alzheimer’s, for which a major need for novel and innovative solutions remains unmet. Use of the optical modality (camera) of the smartphone continues to be highly unutilized for health applications.
Incubation/Acceleration programs accomplishment
We are fortunate to have been accepted into and greatly assisted by our accelerator programs: IBM, Microsoft and NVIDIA.
IBM and NVIDIA, especially, have expressed tremendous bullishness in BioTrillion, and as a result have mobilized resources to help our path to market.
NVIDIA recently highlighted us in an article saying: “Herbst [Head of NVIDIA’s Business Development] calls out BioTrillion as one to watch.”"
Won the competition and other awards
"*Selected (from 300+ applicants) by HLTH (a leading Health Technology industry conference) for their Startup Spotlight Presentation  *Selected (from 700+ applicants) as one of the final eight presenters at HIMSS19 VentureConnect Pitch competition for the “most fundable startup”  *HLTH Top 5% selected for Startup Spotlight Presentation  *Selected and invited to present at additional conferences including: AI Innovation in Life Sciences Summit West, Silicon Valley Science and Technology Forum, AI-Med, KNect365 Life Sciences, Digital Health 4 Pharma, AI Innovation in Life Sciences East, and others throughout 2019"
-10 patents pending around digital biomarkers platform tech, health applications leveraging optical modality + AI tech